What it is: A stabilized fragment of human growth hormone engineered to trigger fat breakdown without raising IGF-1, affecting blood glucose, or producing the growth effects of full GH.
Research suggests: Strong selective fat reduction was demonstrated in multiple preclinical studies; early human trials provided a safety profile but Phase 3 development was never pursued.
Best for: Body composition and fat loss researchers
Key thing to know: Does not affect IGF-1 or blood glucose - a key distinction from full-length GH that makes it a cleaner research tool for studying isolated lipolytic mechanisms.
What is HGH Fragment 176-191?
HGH Fragment 176-191 is a synthetic peptide comprising amino acids 176 through 191 of the human growth hormone (hGH) sequence, with a modification at position 176 to stabilize the fragment. This specific region of the GH molecule was identified by researchers as the segment responsible for GH's fat-mobilizing (lipolytic) activity - distinct from the domains that govern the anabolic and diabetogenic effects of full-length growth hormone.
The rationale for isolating this fragment was to create a compound capable of stimulating fat breakdown without triggering the insulin resistance, IGF-1 elevation, and tissue growth associated with exogenous GH administration. In preclinical studies, this selective activity was demonstrated, generating significant research interest among those studying metabolic interventions and body composition.
HGH Fragment 176-191 was developed and studied by Metabolic Pharmaceuticals in Australia, advancing to Phase 2 human clinical trials before the program was discontinued. It is not FDA approved and is not commercially available as a pharmaceutical product. It exists as a research compound only.
How it works.
Full-length growth hormone exerts its lipolytic effects by binding to GH receptors on adipocytes (fat cells), triggering hormone-sensitive lipase activation and the release of stored fatty acids into circulation for use as energy. Research indicates that this lipolytic signaling is primarily mediated by the C-terminal region of GH - the 176–191 fragment - while the anabolic and IGF-1 stimulating effects are mediated by different structural regions of the molecule.
HGH Fragment 176-191 is proposed to act through a mechanism distinct from the main GH receptor, potentially involving interaction with a fragment-specific receptor or downstream signaling pathway that preferentially activates fat oxidation without the upstream effects on the somatotropic axis. In rodent studies, the fragment has been shown to reduce fat mass, increase lean body mass relative to total body weight, and improve lipid profiles - effects attributed to selective lipolytic activity.
Critically, studies in preclinical studies demonstrated that HGH Fragment 176-191 does not significantly affect blood glucose or insulin sensitivity, and does not produce measurable changes in IGF-1 levels - a key differentiating feature from exogenous GH. Whether this selectivity translates fully to human physiology at the doses studied remains an open research question.
What the research shows.
Animal research - primarily in rodent models - provides the strongest evidence base for HGH Fragment 176-191. Studies consistently show selective fat reduction, preservation of lean mass, and absence of the insulin-desensitizing effects of full GH. These findings are reproducible and mechanistically coherent, generating legitimate scientific interest in the compound's metabolic applications.
Human data is limited and comes primarily from the Phase 2 clinical trials conducted by Metabolic Pharmaceuticals in the early 2000s. These trials enrolled obese adults and showed modest reductions in body weight and fat mass compared to placebo, without significant adverse metabolic effects. However, the trials were not large, the program was discontinued before Phase 3, and the full data set was never published in peer-reviewed form.
This significantly limits the ability to draw firm conclusions about efficacy magnitude, optimal dosing, or long-term safety.
No subsequent large human trials have been conducted. The evidence gap between promising animal data and confirmed human efficacy is the defining characteristic of this compound's research status, and is reflected in its preliminary rating.
Biomarkers to review first.
Research protocols for HGH Fragment 176-191 typically reference the following biomarkers as baseline context. Given its metabolic focus, understanding your current metabolic health markers is especially important before any protocol consideration.
What it's commonly researched with.
In research contexts, HGH Fragment 176-191 is frequently discussed alongside other metabolic peptides and GH secretagogues. The combinations below represent what researchers have studied - not recommendations for use.